In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Private Equity Reinvents Its Take On Biopharma

Executive Summary

Biopharma offers the best PE returns of any health care sector, but represents only about a third of private equity investment in health care as investors remain wary of high-risk R&D and tend to focus on easier targets, which are in limited supply. As the low-hanging fruit disappears, PE investors are looking at new approaches beyond outright purchases and sorting out opportunities in emerging markets.

Advertisement

Related Content

Are Potential Biosimilar Sponsors Still Hesitant About The Pathway Despite Expected Growth?
Vivo Ventures’ Time Arrives As All Eyes Look To China
Nycomed US Crowns New Management; Plans New Direction
With Nycomed, Takeda Satifies Both Strategic And Financial Objectives
Freed From Pfizer, Capsugel May Find More Market Opportunities

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004102

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel